SCHEMBL19050658

SCHEMBL19050658

COc1cc(F)c(F)c(Nc2ccc(C)cc2F)c1NS(=O)(=O)C1CCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.46
MAP2K2 P36507 1/20 0.46
MAPK10 P53779 1/20 0.46
PRKAG1 P54619 1/20 0.46
MAP2K1 Q02750 1/20 0.46
ADCK1 Q86TW2 1/20 0.46
PRKAG2 Q9UGJ0 1/20 0.46
MRGPRX1 Q96LB2 3/20 0.41
HRH1 P35367 1/20 0.41
CSF1R P07333 1/20 0.39
EGFR P00533 1/20 0.37
FGFR1 P11362 1/20 0.37
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
CYP17A1 P05093 1/20 0.37
SCN5A Q14524 6/20 0.37
KCNH2 Q12809 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
KIT P10721 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14619722 0.97 MAP2K1 (0.48) CHEK1MAP2K2MAPK10PRKAG1MAP2K1
SCHEMBL387871 0.89 MAP2K1 (0.58) CHEK1MAP2K2MAPK10PRKAG1MAP2K1
SCHEMBL685422 0.85 MAP2K1 (0.61) CHEK1MAP2K2MAPK10PRKAG1MAP2K1
SCHEMBL19050690 0.84 MRGPRX1 (0.41) CHEK1MAP2K2MAPK10PRKAG1MAP2K1
SCHEMBL19050665 0.83 MAP2K1 (0.48) CHEK1MAP2K2MAPK10PRKAG1MAP2K1
SCHEMBL19050669 0.80 MRGPRX1 (0.40) MAP2K2MAP2K1MRGPRX1HRH1TLR4
SCHEMBL392369 0.80 MAP2K1 (0.47) CHEK1MAP2K2MAPK10PRKAG1MAP2K1
SCHEMBL391647 0.80 MRGPRX1 (0.44) MAP2K2MAP2K1MRGPRX1HRH1KIT
SCHEMBL19050673 0.79 MRGPRX1 (0.40) MAP2K2MAP2K1MRGPRX1HRH1TLR4
SCHEMBL20385592 0.78 MAP2K1 (0.60) CHEK1MAP2K2MAPK10PRKAG1MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170183333-A1 DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK ARDEA BIOSCIENCES, INC. (US) 2017-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170183333-A1 DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK BRAF, NRAS, MAP3K2 CHEK1 260/4885MAP2K2 48/4885MAPK10 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.